Clinical

A 4-million-person study finds unvaccinated COVID-19 infection raises myocarditis, pericarditis, and death risk far more than the Pfizer vaccine.

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.

County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy People 2030 target in 2019.

Major depressive disorder (MDD) is a heterogeneous disorder with many unique symptom combinations.

Tara Graff outlined a practical framework for community oncology practices looking to establish safe and successful programs with novel regimens, emphasizing that while tafasitamab-based combinations can be adopted with relatively minimal operational changes, bispecific antibodies require more deliberate infrastructure investment, but that every community site has the capacity to build this capability with the right approach.

Hepatitis B and hepatitis C behave nothing alike once treatment succeeds. This episode explains why hepatitis B's genomic integration makes true virologic cure fundamentally more complex than hepatitis C clearance.

Tara Graff highlighted the significance of 2025 as a landmark year for RRFL treatment, with the June 2025 approval of tafasitamab plus R² and the November 2025 approval of epcoritamab plus R² representing two major additions to the NCCN guidelines that meaningfully expand the second-line treatment options available to follicular lymphoma patients beyond the R² backbone and signaling a clear directional shift toward novel, non-chemotherapy combinations that can deliver progression-free survival measured in years.

Welcome back to another AJMC Peer Exchange series. In this episode titled, "The Burden of Major Depressive Disorder: Setting the Stage for Managed Care."

Tara Graff discussed her experience with epcoritamab-based combinations in follicular lymphoma, noting that her practice's participation in both epcoritamab monotherapy and combination therapy trials has provided her with firsthand familiarity with the regimen and that the efficacy data, particularly the overall response and complete response rates associated with epcoritamab plus R², is compelling.

Guideline inconsistency and treatment thresholds continue to create gaps in chronic hepatitis B care, particularly in primary care settings. This episode also examines what functional cure means for cancer risk and long-term antiviral safety.

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy.

Authors explore which biomarkers could be predictive for a forthcoming study using circulating tumor DNA in DLBCL.

Different inclusion criteria, different primary endpoints, different eras of the pandemic: Dr. Rosmarin unpacks why the pivotal topical and oral vitiligo trials resist direct comparison, and where a meta-analysis might still help.

A payer's view of competing JAK mechanisms centers less on selectivity data and more on price. Jason explains why a wide cost gap between topical and oral therapies will likely keep the topical option as first-line policy.

Authors noted that a grocery assistance benefit in commercial health plans was linked to fewer diabetes complications and improved medication adherence.

Lifetime colorectal cancer (CRC) risk was highest in highly developed countries, according to a global population-based study.

The approval is based on the Phase 2/3 ENERGY trial, which demonstrated durable hemoglobin response.

Learn how doctors spot mild cognitive impairment early using MoCA, Mini-Cog, caregiver insights, and blood biomarkers to guide MRI/PET treatment.

Clinicians unpack Alzheimer’s rising risk, why early detection and lifestyle prevention matter, and how delaying onset could cut costs dramatically.

Marc A. Sala, MD, explains why frequent exacerbations signal it's time to reassess bronchiectasis care, plus the promise of gene-based screening.

Early findings from the CDAF-Relink program highlight gaps in re-engagement, outreach barriers, and opportunities to reconnect patients to care.

There are significant, and uneven, knowledge gaps among physicians treating patients with mantle cell lymphoma and chronic lymphocytic leukemia across countries and settings, a survey finds.

AI-driven platform boosts screening capacity 41%, cuts manual review by 75% across Ochsner's 47 hospitals and 370 clinics.

Almandoz explained that while GLP-1 receptor agonism alone delivers meaningful benefits in appetite regulation, satiety, glycemic control, and cardiorenal and liver outcomes, the addition of glucagon receptor agonism introduces a distinct and complementary layer of biology that goes beyond weight loss alone to address the metabolic drivers most closely linked to insulin resistance, cardiometabolic risk, and MASH progression.